{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:41:39Z","timestamp":1781682099461,"version":"3.54.5"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The options for frontline chronic lymphocytic leukemia (CLL) treatment continue to expand. Therapies include monotherapy with a Bruton's tyrosine kinase inhibitor (BTKi), doublet therapies such as venetoclax with intravenous obinutuzmab or an oral BTKi, and triplet therapy combining BTKi, venetoclax, and CD20 antibody. Treatment duration also is increasingly variable, from fixed duration to utilization of undetectable minimal residual disease (uMRD) to determine optimal treatment completion. Currently, the best option for an individual patient requires a multifaceted approach considering the individual's cytogenetics, comorbidities, and personal preferences, including time-limited therapy vs continuous treatment. In this article, we outline the current state of frontline CLL including ongoing questions and future directions.<\/jats:p>","DOI":"10.1182\/hematology.2025000686","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:14Z","timestamp":1764943754000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Updates in the management of newly diagnosed chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"2025","author":[{"given":"Kristen","family":"McClellan","sequence":"first","affiliation":[{"name":"Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sitlinger","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"25","key":"2025120616341617600_hem2025000686C1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2025120616341617600_hem2025000686C2","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00277-021-04600-1","article-title":"Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985\u20132017)","volume":"100","author":"Alrawashdh","year":"2021","journal-title":"Ann Hematol"},{"key":"2025120616341617600_hem2025000686C3","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 3.2025)","author":"NCCN","year":"2025"},{"issue":"21","key":"2025120616341617600_hem2025000686C4","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025120616341617600_hem2025000686C5","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"26","key":"2025120616341617600_hem2025000686C6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025120616341617600_hem2025000686C7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"2025120616341617600_hem2025000686C8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow- up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2025120616341617600_hem2025000686C9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hon.2349","article-title":"Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia","volume":"35","author":"Le Bris","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"2025120616341617600_hem2025000686C10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"31","key":"2025120616341617600_hem2025000686C11","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120616341617600_hem2025000686C12","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2025120616341617600_hem2025000686C13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025120616341617600_hem2025000686C14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025120616341617600_hem2025000686C15","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1200\/JCO.2025.43.16_suppl.7011","article-title":"SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"43","author":"Tam","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10232","key":"2025120616341617600_hem2025000686C16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2025120616341617600_hem2025000686C17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"issue":"36","key":"2025120616341617600_hem2025000686C18","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025120616341617600_hem2025000686C19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025120616341617600_hem2025000686C20","first-page":"S191","article-title":"The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-na\u00efve chronic lymphocytic leukemia: final analysis from the phase 3 GAIA\/CLL13 trial. EHA2025 Congress","author":"F\u00fcrstenau","year":"2025"},{"issue":"10","key":"2025120616341617600_hem2025000686C21","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2025120616341617600_hem2025000686C22","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"issue":"21","key":"2025120616341617600_hem2025000686C23","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120616341617600_hem2025000686C24","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025120616341617600_hem2025000686C25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2024-203269","article-title":"First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): Glow study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis","volume":"144","author":"Niemann","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2025120616341617600_hem2025000686C26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616341617600_hem2025000686C27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"AMPLIFY investigators fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med."},{"issue":"Suppl 16","key":"2025120616341617600_hem2025000686C28","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2024.42.16_suppl.7009","article-title":"Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study","volume":"42","author":"Wierda","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616341617600_hem2025000686C29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2025120616341617600_hem2025000686C30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2023-178298","article-title":"Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study","volume":"142","author":"Hillmen","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2025120616341617600_hem2025000686C31","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and venetoclax for patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA Arm D results","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025120616341617600_hem2025000686C32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open- label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025120616341617600_hem2025000686C33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/ TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2025120616341617600_hem2025000686C34","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"2025120616341617600_hem2025000686C35","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"31","key":"2025120616341617600_hem2025000686C36","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025120616341617600_hem2025000686C37","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2023.41.16_suppl.7500","article-title":"Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)","volume":"41","author":"Woyach","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025120616341617600_hem2025000686C38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025120616341617600_hem2025000686C39","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood.V128.22.3226.3226","article-title":"Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up","volume":"128","author":"Rawstron","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025120616341617600_hem2025000686C40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 captivate study","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/45\/2470079\/45mcclellan.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/45\/2470079\/45mcclellan.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:28Z","timestamp":1765056868000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/45\/556917\/Updates-in-the-management-of-newly-diagnosed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000686","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}